Antioxidants in nephrology: bardoxolone and diabetic nephropathy
- Authors: - -
- Issue: No 3 (2013)
- Pages: 4-6
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/261743
- ID: 261743
Cite item
Open Access
Access granted
Abstract
Results of clinical trials, assessing the efficacy and safety of bardoxolone as a nephroprotective agent are discussed.
Full Text
References
- Wardle E.N. Cellular oxidative processes in relation to renal diseases. Am J Nephrol. 2005; 25(1): 13-22.
- Rojas-Rivera J., Ortiz A., Egido A. Antioxidants in kidney disease. The impact of bardoxolone methyl. Int J Nephrol. 2012; doi: 10.1155/2012/321714 doi: 10.1155/2012/321714 клиническая нефрология З - 2013
- Lazaro A., Gallego-Delgado P., Justo P. et al. Long-term blood pressure control prevents oxidative renal injury. Antioxidants and Redox Signalling. 2005; 7(9-10): 1285-1293.
- Lee H.B., Yu M.R., Yang Y. et al. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol. 2003; 14 (8 Suppl 3): S241-S245.
- Budislavjevic M.N., Hodge L., Barber K. et al. Oxidative stress in the pathogenesis of experimental mesangial proliferative glomerulonephritis. Am J Physiol. 2003; 285(6): F1138-F1148.
- Foster M.H. T-cells and B-cells in lupus nephritis. Semin Nephrol. 2007; 27(1): 47-58.
- Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414 (6865): 813-820.
- Jaiswal A.K. Nrf2 signalling in coordinated activation of antioxidant gene expression. Free Radic Biol Med. 2004; 36(10): 1199-1207.
- Unzgwari Z., Bailey-Downs L., Gautam T. et al. Adaptive induction NF E2-derived factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia. Am J Physiol Heart Circ Physiol. 2011; 300(4): H1133-H1140.
- Thomas M.C. Bardoxolone: augmenting the Yin in chronic kidney disease. Diab Vasc Dis Res. 2011; 8(4): 303-304.
- Kim S.B., Pandita R.K., Eskiocak U. et al. Targeting of Nrf2 induces DNA damage signaling and protects colonic epithelial cells from ionizing radiation. Proc Natl Acad Sci U S A. 2012; 109(43): E2949-2955.
- Meyer C. Bardoxolone, a novel oral anti-inflammatory agent shown to improve renal function. Nationa Kidney Foundation Spring Clinical Meeting 2009 (abstr).
- Pergola P.E., Krauth M., Huff J.W. et al. Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. Am J Nephrol. 2011; 33(5): 469-476.
- Warnock D.G., Hebbar S., Bargman J. et al. Prospective safety study of bardoxolone methyl in patients with type 2 diabetes mellitus, end-stage renal disease and peritoneal dialysis. Contrib Nephrol. 2012; 178: 157-163.
- Ding Y., Stidham R.D., Bumeister R. et al. The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells. Kidney Int. 2012 Dec 12. doi: 10.1038/ki.2012.393. [Epub ahead of print].
- Wu Q.Q., Wang Y., Senitko M. et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARy, and HO-1. Am J Physiol Renal Physiol. 2011; 300(5): F1180-F1192.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3: 1-150
- Reisman S.A., Chertow G.M., Hebbar S. et al. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol. 2012; 23(10): 1663-1673.
- Pergola P.E., Raskin P., Toto R.D. et al. for BEAM Study Investigators. Bardoxolone methyl and kidney function in type 2 diabetes. N Engl J Med 2011; 365: 327-336.
- Jun M., Venkataraman V., Razavian M. et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev. 2012; 10: CD008176. doi: 10.1002/14651858.CD008176.pub2.
Supplementary files
